Centus Biotherapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsCentus Biotherapeutics

Centus Biotherapeutics

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Equidacent	Bevacizumab	2020-09-24		Renal cell carcinoma , Colorectal neoplasms , Breast neoplasms , Ovarian neoplasms , Non-small-cell lung carcinoma , Glioblastoma , Fallopian tube neoplasms , Kidney neoplasms , Uterine cervical neoplasms , Peritoneal neoplasms

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

non-small-cell lung carcinoma

intervertebral disc degeneration

Globulin, immune

,

,

urogenital neoplasms

,

male genital neoplasms

,

,

prostatic neoplasms

,

,

,

ovarian epithelial carcinoma

,

renal cell carcinoma

,

colorectal neoplasms

,

pancreatic neoplasms

,

malignant pleural effusion

,

castration-resistant prostatic neoplasms

,

inflammatory breast neoplasms

,

head and neck neoplasms

,

squamous cell carcinoma

,

synovial sarcoma

,

ureteral neoplasms

,

adolescent development

,

male breast neoplasms

,

esophageal squamous cell carcinoma

,

squamous cell carcinoma of head and neck

,

non-small-cell lung carcinoma

,

,

ovarian neoplasms

,

,

neoplasm metastasis

,

stomach neoplasms

,

peritoneal neoplasms

,

fallopian tube neoplasms

,

,

,

urologic neoplasms

,

urethral neoplasms

,

urinary bladder neoplasms

,

transitional cell carcinoma

,

female genital neoplasms

,

pelvic neoplasms

,

unknown primary neoplasms

,

breast neoplasms

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use